The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions

• Published in: Journal of clinical medicine Vol. 12; no. 18; p. 6012
• Main Authors: Laface, Carmelo, Giuliani, Francesco, Melaccio, Assunta, Pappagallo, Maria Nicla, Santoro, Anna Natalizia, Perrone, Martina, De Santis, Pierluigi, Guarini, Chiara, Carrozzo, Daniela, Fedele, Palma
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01-09-2023; MDPI
• Subjects: Age; Aged patients; Antimitotic agents; Antineoplastic agents; Breast cancer; Cancer therapies; Care and treatment; Chemotherapy; Clinical medicine; Cyclin-dependent kinases; Dosage and administration; Endocrine therapy; Estrogens; Geriatrics; Health aspects; Kinases; Life expectancy; Metastasis; Mutation; Older people; Ovaries; Patients; Polypharmacy; Review; Tumors; Womens health; Italy
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12186012

Breast cancer (BC) in elderly women is an increasing health issue due to demographic changes. BC tends to present later and may receive less than standard treatment options. More often, BC in elderly patients is endocrine-positive (HR+). The treatment of elderly patients with metastatic BC (mBC) represents a therapeutic challenge. In recent years, the treatment landscape of patients that are HR+/Her2-negative has changed due to the introduction in clinical practice of new targeted drugs, which have improved patient outcomes. Elderly patients are a small percentage of all patients enrolled in clinical trials and, to date, there are no standardized guidelines that define the best treatment option for this patient population. This can lead to undertreatment or overtreatment, impacting patient morbidity and mortality. Geriatric Assessment tools to tailor the treatment in elderly patients are underused because they are long and difficult to apply in a busy routine clinical practice. For all these reasons, there is an urgent need to produce data about the best treatment for elderly patients with HR+ mBC. Herein, we report data from randomized clinical trials and real-world evidence on the therapeutic options for HR+ Her2-negative mBC elderly patients and explore future treatment directions.